ライフサイエンスコーパス: scintigraphy

1 %, 81%, and 86%, respectively, for leukocyte scintigraphy.

2 abeled mashed potato meal was measured using scintigraphy.

3 tion in rabbits were investigated with gamma-scintigraphy.

4 uptake on (99m)Tc-PAMA-cobalamin whole-body scintigraphy.

5 s purpose are ultrasonography and MIBI-Tc99m scintigraphy.

6 uclide studies consisting of PET-CT and MIBG scintigraphy.

7 ter perfusion defect on myocardial perfusion scintigraphy.

8 d further characterized with PET-CT and MIBG scintigraphy.

9 amyloid load was measured by serum amyloid P scintigraphy.

10 cal planning and is superior to conventional scintigraphy.

11 afe, cost-effective alternative to sestamibi scintigraphy.

12 tion exposure with similar cost to sestamibi scintigraphy.

13 al of the infused nutrient was determined by scintigraphy.

14 e basis of method ultrasonography and planar scintigraphy.

15 cociliary clearance was measured using gamma scintigraphy.

16 tive expression of tumor burden seen on bone scintigraphy.

17 ressing tumor xenografts and imaged by gamma-scintigraphy.

18 wed good agreement with myocardial perfusion scintigraphy.

19 ith Paget disease were true positive only at scintigraphy.

20 (US) and technetium 99m ((99m)Tc) sestamibi scintigraphy.

21 high-fat) diet for 25 wk and imaged by gamma-scintigraphy.

22 assic symptoms of gastroparesis but negative scintigraphy.

23 compared with pretherapy ( 123)I whole-body scintigraphy.

24 sclerotic disease using myocardial perfusion scintigraphy.

25 st meals have been used for gastric emptying scintigraphy.

26 treatment (80%/65%) sensitivity of 123I-MIBG scintigraphy.

27 to facilitate quantitative analyses by gamma-scintigraphy.

28 hono-1,2-propanodicarboxylic-acid (DPD) bone scintigraphy.

29 practice guidelines and the current role of scintigraphy.

30 intestinal radiography, and gastrointestinal scintigraphy.

31 catheter and small intestinal transit using scintigraphy.

32 and whole-body MRI were performed after bone scintigraphy.

33 nts each) were assessed by sequential planar scintigraphy (1, 5, and 24 h after injection).

34 Gastric emptying (scintigraphy, 100 mL of Ensure (Abbott Australia, Kurnel

35 e injected intravenously, followed by (123)I scintigraphy, (124)I PET imaging, and (131)I therapy.

36 Compared with conventional scintigraphy, (64)Cu-DOTATATE PET identified additional

37 ith a combination of whole-body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs. 83.0%

38 < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs. 65.9

39 contrast enhanced MR urography for RS renal scintigraphy acceptable.

40 Bone scintigraphy accurately diagnoses osteomyelitis in bones

41 The combined use of mammography and scintigraphy achieved 100% sensitivity.

42 g the performance and interpretation of lung scintigraphy across 3 different countries.

43 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (18)F-FDG PET in neuroblastoma.

44 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (18)F-FDG PET, using tumor histology as

45 ts and might be complementary to (123)I-MIBG scintigraphy and (18)F-FDG PET.

46 techniques ((99m)Tc-galactosyl serum albumin scintigraphy and (99m)Tc-mebrofenin hepatobiliary scinti

47 Results of bone scintigraphy and biochemical investigations were analyze

48 using specific search terms, including both scintigraphy and C13-octanoic acid breath test.

49 Patients underwent myocardial scintigraphy and cells were injected in the artery suppl

50 It is superior to (131)I-MIBG scintigraphy and conventional imaging (CT/MR imaging) fo

51 131)I-metaiodobenzylgunanidine ((131)I-MIBG) scintigraphy and conventional imaging (CT/MR imaging) of

52 Skeletal scintigraphy and cross-sectional imaging confirmed wides

53 Although nuclear scintigraphy and CTA had similar sensitivity and specifi

54 The difference in sensitivity between scintigraphy and mammography was not statistically signi

55 patic amyloid load, as shown by means of SAP scintigraphy and measurement of extracellular volume by

56 dels including the visual assessment of bone scintigraphy and other relevant covariates.

57 Peptide receptor scintigraphy and peptide receptor radionuclide therapy a

58 xamples of theranostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy o

59 such as JR11 might enhance peptide receptor scintigraphy and peptide receptor radionuclide therapy o

60 Peptide receptor scintigraphy and peptide receptor radionuclide therapy u

61 They received 111Indium (111ln)-J591 for scintigraphy and PK, followed 2 weeks later by J591 with

62 The annual use of bone scintigraphy and radiotracer therapies was unchanged.

63 Clinicians currently use planar scintigraphy and single-photon emission computed tomogra

64 CCK2R tumor xenografts and examined by gamma scintigraphy and SPECT/CT.

65 to diagnose dysfunction (dynamic gallbladder scintigraphy and sphincter manometry) is controversial.

66 Most importantly, sstr scintigraphy and sstr PET/CT can distinguish patients wh

67 2 or 3 myocardial radiotracer uptake on bone scintigraphy and the absence of a monoclonal protein in

68 sm of these coated virus particles by (123)I scintigraphy and to evaluate their therapeutic potential

69 aresis, delayed gastric emptying by standard scintigraphy and typical symptoms for more than 3 months

70 the results with those for (99m)Tc-MDP bone scintigraphy and whole-body MRI.

71 False-negative results on 123I-MIBG scintigraphy and/or [18F]FDA-PET were not predicted by g

72 ly by [(123)I]metaiodobenzylguanidine (MIBG) scintigraphy and/or bone marrow (BM) histology (stratum

73 iods; gastrointestinal transit (by validated scintigraphy) and bowel function (by daily diaries) were

74 vailable bone scintigraphy, white blood cell scintigraphy, and (18)F-FDG PET/CT results.

75 0.2% for (18)F-DA PET, 76.0% for (123)I-MIBG scintigraphy, and 22.0% for SRS.

76 5.4% for (18)F-DA PET, 63.4% for (123)I-MIBG scintigraphy, and 64.0% for SRS.

77 ely 93% and 100% for (123) I-MIBG myocardial scintigraphy, and 90% and 76% for (123) I-FP-CIT SPECT.

78 st computed tomography scan, liver MRI, bone scintigraphy, and axial skeleton MRI have been proven su

79 Computed tomography, bone scintigraphy, and lumbar spine x-rays were performed at

80 rity as measured by both radiograph and bone scintigraphy, and synovial fluid IL-1beta was associated

81 ic diagnosis was obtained in all cases after scintigraphy, and the scintigraphic findings were correl

82 hodologies for (99m)Tc-sestamibi parathyroid scintigraphy are in clinical use.

83 of serum bilirubin levels and hepatobiliary scintigraphy are showing strong correlation with long-te

84 ator and support further exploration of bone scintigraphy as an imaging biomarker in CRMPC.

85 radiation-associated procedure; use of lung scintigraphy as the preferred test in the setting of a n

86 various imaging examinations, including bone scintigraphy as well as CT and MRI of the lumbosacral sp

87 evascularization as detected with myocardial scintigraphy at 12 months.

88 imilar to both CTA and ventilation-perfusion scintigraphy, at lower cost and with lower radiation dos

89 All had negative conventional CT and bone scintigraphy before enrollment.

90 Moreover, scintigraphy better assessed disease extent than did mam

91 d with bone marrow histology and bone marrow scintigraphy (BMS), the gold standard techniques in this

92 assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who hav

93 Skeletal scintigraphy (bone scan) is very sensitive in the detect

94 of cartilage remodeling by (99m)Tc-NTP 15-5 scintigraphy, bone damages by (99m)Tc-hydroxymethylene d

95 s of overuse defined as combined use of bone scintigraphy (BS) and PET, which current guidelines reco

96 graphy/computed tomography (PET/CT) and bone scintigraphy (BSc) in women with suspected MBC.

97 similar to that in PIOPED II, results of V/Q scintigraphy can be diagnostically definitive in a major

98 igraphy and (99m)Tc-mebrofenin hepatobiliary scintigraphy) can measure both total and future remnant

99 valuated using hematologic parameters, renal scintigraphy, clinical data, and the prostate-specific a

100 Perfusion scintigraphy combined with chest radiography can provide

101 patient has been performed with radiography, scintigraphy, computed tomography, magnetic resonance im

102 catheterization, ventilation-perfusion lung scintigraphy, computerized tomography, and/or pulmonary

103 any nodal and lung metastases from dogs, and scintigraphy confirmed folate uptake in both primary and

104 se in 1 of 7 patients (14%), while sestamibi scintigraphy correctly predicted multiglandular disease

105 pre-angiography test, compared with nuclear scintigraphy, CTA reduced overall the number of imaging

106 eased from 3.8% to 56.6%, and use of nuclear scintigraphy decreased from 83.3% to 50.6% following pro

107 Dynamic parathyroid CT and sestamibi scintigraphy delivered mean radiation doses of 5.56 and

108 In our series, BSGC scintigraphy demonstrated a slightly higher sensitivity

109 thyroid CT and a mean of $1112 for sestamibi scintigraphy, depending on the type and amount of radiot

110 In two patients, 111In-pentetreotide scintigraphy detected liver lesions that were negative o

111 combination of CT/MR imaging and (131)I-MIBG scintigraphy detected only 53 of 78 (67.9%) lesions and

112 a of the gall bladder is rare and hence bone scintigraphy does not form a part of the routine work-up

113 investigated further with CT, MRI, or renal scintigraphy done before and after administration of an

114 Bone scintigraphy enables the diagnosis of cardiac ATTR amylo

115 s well standardized as gastric emptying (GE) scintigraphy, esophageal transit scintigraphy, if perfor

116 wever, there are cohorts of patients in whom scintigraphy findings are negative or equivocal.

117 t either dynamic parathyroid CT or sestamibi scintigraphy for any etiology of hyperparathyroidism fro

118 r 55%+/-11%), underwent myocardial perfusion scintigraphy for documentation of reversible perfusion d

119 s superior to whole-body MRI and (99m)Tc-MDP scintigraphy for evaluation of skeletal disease extent.

120 Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment

121 contrast enhanced MR urography and RS renal scintigraphy for measurement of SRF split renal function

122 e, replace technetium-99m diphosphonate bone scintigraphy for osteomedullary metastasis assessment.

123 ate than with single-phase (99m)Tc-sestamibi scintigraphy for planar imaging, SPECT, and SPECT/CT.

124 ing as a first-line alternative to sestamibi scintigraphy for preoperative localization of parathyroi

125 lization should undergo both angiography and scintigraphy for the assessment of hepaticoenteric arter

126 te scintigraphy (LS), and Gallium-67 citrate scintigraphy for the diagnosis of CIED infection.

127 e performance of (18)F-FDG PET and leukocyte scintigraphy for the diagnosis of PVE in 39 patients.

128 MRU was shown to be superior to renal scintigraphy for the diagnosis of pyelonephritis and ren

129 nfirmation of the performance of (123)I-MIBG scintigraphy for the evaluation of patients with known o

130 f (18)F-DA PET is not available, (123)I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS

131 l distribution (IMD) during gastric emptying scintigraphy (GES) allows for a simple measure of FA.

132 ging group (gadoterate meglumine), and renal scintigraphy group ((99m)Tc).

133 In the MR imaging and renal scintigraphy groups, there were significant changes in s

134 ent; 49, disease absent), (123)I-MIBG planar scintigraphy had a sensitivity and specificity of 82%.

135 GE scintigraphy has undergone much-needed standardization.

136 ) I-FP-CIT SPECT and (123) I-MIBG myocardial scintigraphy have similar sensitivity for detecting DLB,

137 ptying (GE) scintigraphy, esophageal transit scintigraphy, if performed in a comprehensive manner inc

138 gation test 1 week later and interpreted the scintigraphy images at the end of the study.

139 Planar scintigraphy imaging followed by SPECT/CT imaging was ob

140 (Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and

141 126425; Meta-Iodobenzylguanidine [123I-mIBG] Scintigraphy Imaging in Patients With Heart Failure and

142 ll with historical data derived using (131)I scintigraphy imaging, whereas the response rate for LMs

143 dimercaptosuccinic acid ((99m)Tc-DMSA) renal scintigraphy in 2 cases of preemptive LKT demonstrated p

144 mated CT densitometry, and (99m)Tc perfusion scintigraphy in 28 patients being evaluated for LVR.

145 ide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PGL.

146 ility of (99m)Tc-pyrophosphate ((99m)Tc-PYP) scintigraphy in AL versus ATTR.

147 independent prognostic value of (123)I-mIBG scintigraphy in assessment of patients with HF.

148 cation of SPECT/CT technology to radioiodine scintigraphy in both diagnostic and post-therapy setting

149 lness of breast-specific gamma-camera (BSGC) scintigraphy in DCIS identification, describing the scin

150 nd dog bladder tissues together with nuclear scintigraphy in dogs to monitor iUC folate uptake.

151 of (18)F-FDG PET and radiolabeled leukocyte scintigraphy in IE patients has already been reported.

152 with Tc-99m-mercapto-acetyltriglycin (MAG3) scintigraphy in living kidney donation.

153 tigated the reliability of (99m)Tc-sestamibi scintigraphy in monitoring changes in bone marrow involv

154 of a combination of whole-body MRI and bone scintigraphy in patients with breast and prostate cancer

155 used 3-d protocol for somatostatin receptor scintigraphy in patients with gastroenteropancreatic neu

156 rgery, dynamic CT is comparable to sestamibi scintigraphy in patients with hyperparathyroidism.

157 m)Tc-mercaptoacetyltriglycine ((99m)Tc-MAG3) scintigraphy in patients with renal insufficiency.

158 dy to ascertain the diagnostic value of bone scintigraphy in this disease.

159 We assessed the value of (99m)Tc-HMPAO-WBC scintigraphy including SPECT/CT acquisitions in a series

160 At both SPECT/CT and planar scintigraphy, increased uptake of (99m)Tc-liposomal doxo

161 This pilot study of 99mTc-EC20 scintigraphy indicates that the agent is safe and well t

162 pporting the hypothesis that whole-body bone scintigraphy is a means of quantifying the total-body bu

163 rointestinal tract, gastrointestinal transit scintigraphy is a uniquely suited noninvasive, quantitat

164 Splenic scintigraphy is an economical, accessible and accurate t

165 inated metaiodobenzylguanidine ((123)I-mIBG) scintigraphy is an established imaging method in neurobl

166 Gastric emptying scintigraphy is considered to be the gold standard for d

167 netriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicine imaging m

168 was the first widely used agent for skeletal scintigraphy, it quickly fell into disuse after the intr

169 scanning took less than 5 minutes, sestamibi scintigraphy lasted a mean time of 306 minutes.

170 reasing organ amyloid burden assessed at SAP scintigraphy (liver, rs = 0.54; spleen, rs = 0.57).

171 mates from 256-slice CTPA and lung perfusion scintigraphy (LPS) for comparison.

172 y and computed tomography, labeled leukocyte scintigraphy (LS), and Gallium-67 citrate scintigraphy f

173 No studies for (67)Ga citrate scintigraphy met the inclusion criteria.

174 ve echocardiogram and a myocardial perfusion scintigraphy (MPS) at inclusion.

175 linical value of stress myocardial perfusion scintigraphy (MPS) in elderly patients (> or =75 years o

176 severity of ischemia on myocardial perfusion scintigraphy (MPS) is commonly used to risk-stratify pat

177 recurring; thus, stress myocardial perfusion scintigraphy (MPS) is widely used to identify ischemia i

178 Myocardial perfusion scintigraphy (MPS) was used to assess adenosine-induced

179 Compared with stress myocardial perfusion scintigraphy (MPS), CCTA was associated with an increase

180 Whether abnormal myocardial perfusion scintigraphy (MPS), dobutamine stress echocardiography (

181 opriateness ratings for myocardial perfusion scintigraphy (MPS), stress echocardiography (STE), or co

182 trated a higher sensitivity than (123)I-MIBG scintigraphy (n = 18; P = 0.0455) or (18)F-FDG PET (n =

183 If neither conventional bone scintigraphy nor NaF PET were available, referring physi

184 c MRI with gadolinium and (123)I-labeled SAP scintigraphy not only assist in evaluation of patients w

185 n the results of (18)F-FDG PET and leukocyte scintigraphy occurred in 12 patients (31%).

186 myocardial ischemia on myocardial perfusion scintigraphy of all parameters was compared using receiv

187 In vivo (123)I scintigraphy of nude mice revealed significantly reduced

188 Leukocyte scintigraphy offers a higher specificity, however, than

189 ergoing restaging with somatostatin receptor scintigraphy on a modern SPECT/CT device were enrolled i

190 in 54 of 62 patients (87%), while sestamibi scintigraphy only correctly lateralized 90 of 122 adenom

191 egions that were false negative on 123I-MIBG scintigraphy or [18F]FDA-PET were detected by [18F]FDG-P

192 nsitive and specific than either (67)gallium scintigraphy or computerized tomography, providing a mor

193 n in ischemic burden on myocardial perfusion scintigraphy or in the safety endpoints of major bleedin

194 ional CT, appropriately supplemented by bone scintigraphy or other modalities), was defined prospecti

195 mptying, based on (99m)technetium-mebrofenin scintigraphy or post-prandial variations in gallbladder

196 ecause it is more sensitive than (123)I-MIBG scintigraphy or SRS.

197 ardiac study (echocardiography, radionuclide scintigraphy, or cardiac catheterization).

198 dicine modalities: (18)F-DA PET, (123)I-MIBG scintigraphy, or SRS.

199 ly more lesions than (111)In-DTPA-octreotide scintigraphy (P < 0.001).

200 lene-diphosphonate ((99m)Tc-HDP) planar bone scintigraphy (pBS), (99m)Tc-HDP SPECT/CT, (18)F-NaF PET/

201 Gastrointestinal bleeding scintigraphy performed with (99m)Tc-labeled autologous e

202 Standard scintigraphy plays a crucial role, and data from positro

203 In patients with RA, scintigraphy plays a key role in the differential diagno

204 Parathyroid scintigraphy plays a major role in defining the surgical

205 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy plays an important role in the diagnostic e

206 After baseline scintigraphy, PMPA was injected in doses of 0.2-50 mg/kg

207 BSGC scintigraphy proved to be a highly sensitive diagnostic

208 Radionuclide renal scintigraphy provides important functional data to assis

209 Therefore, posttherapy ( 131)I whole-body scintigraphy provides incremental clinically relevant in

210 trinary interpretation strategy for V/Q lung scintigraphy provides outcomes similar to traditional pr

211 invasive imaging of NIS expression by (123)I scintigraphy-provides detailed characterization of in vi

212 an include a ultrasonography (US) and planar scintigraphy (PS) whose characterized by noninvasive.

213 gamma-Scintigraphy quantified the uptake of studied radiolabel

214 before and immediately after diuretic renal scintigraphy (reference standard for presence of urinary

215 Bone scintigraphy remains the most commonly used imaging tool

216 ((123)I-MIBG) was examined by PET and planar scintigraphy, respectively.

217 been excluded, 6 had true-negative leukocyte scintigraphy results but false-positive (18)F-FDG PET re

218 and heart disease on (123) I-MIBG myocardial scintigraphy results might have been overestimated.

219 requency Questionnaire, and gastric emptying scintigraphy results were analyzed.

220 (99m)Tc-HMPAO-WBC scintigraphy results were correlated with transthoracic

221 FDG PET results but false-negative leukocyte scintigraphy results.

222 (18)F-FDG PET results and negative leukocyte scintigraphy results.

223 Scintigraphy revealed abnormal hot spots in subcutaneous

224 1)I ablation, posttherapy ( 131)I whole-body scintigraphy revealed new IAFs in 18% and clinical upsta

225 peutic (131)I imaging comprised a whole-body scintigraphy scan and a SPECT/CT scan of the neck to dis

226 mission computed tomography and quantitative scintigraphy (see scheme).

227 Presently, (99m)Tc-mebrofenin hepatobiliary scintigraphy seems to be the most valuable quantitative

228 Thus, BSGC scintigraphy should represent a useful adjunctive tool i

229 (131)I-MIBG scintigraphy showed only 30 of the 78 lesions and was in

230 so underwent serum amyloid P (SAP) component scintigraphy so that specific organ involvement by amylo

231 the present study used (99m)Tc-MAA SPECT/CT scintigraphy (SPECT with integrated low-dose CT) to eval

232 In addition to planar whole-body scintigraphy, SPECT/CT of the neck was performed using a

233 )In-DTPA(0)]octreotide somatostatin receptor scintigraphy (SRS) before treatment, and who had soft-ti

234 ing studies in the pre-somatostatin receptor scintigraphy (SRS) era, and 23 patients in the post-SRS

235 ative conventional and somatostatin receptor scintigraphy (SRS) results were studied.

236 dine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide in nonmeta

237 -up comprised CT scan, (111)In-pentetreotide scintigraphy (SRS), and (18)F-FDG PET.

238 MR, together with the somatostatin receptor scintigraphy (SRS), in each clinically suspicious case.

239 de (HYNIC)-octreotide (somatostatin receptor scintigraphy [SSRS]) SPECT/CT, (68)Ga-DOTATATE PET/CT, a

240 (EXINI Bone(BSI)) was obtained for baseline scintigraphy studies and follow-up scans after 3 cycles

241 questionnaires, and 4-hour gastric emptying scintigraphy studies were obtained from patients with IG

242 Bone scintigraphy studies were reviewed and graded according

243 ide PET, compared with (99m)Tc-diphosphonate scintigraphy, support the reconsideration of (18)F-fluor

244 se severity as determined by late-phase bone scintigraphy, supporting the hypothesis that whole-body

245 t, include magnetic resonance imaging (MRI), scintigraphy techniques (SPECT) and PET.

246 By nuclear scintigraphy, the biodistribution of Pam-Doxo-NPs demons

247 but correctly negative at (99m)Tc-HMPAO-WBC scintigraphy: these patients had marantic vegetations.

248 med using technetium-pertechnetate and gamma-scintigraphy to assess determining factors for radioupta

249 chelatable iron; quantitative hepatobiliary scintigraphy to assess hepatic uptake and excretion of c

250 positive findings on (111)In-DTPA-octreotide scintigraphy to determine whether (68)Ga-DOTATATE PET is

251 roaggregated albumin ((99m)Tc-MAA) perfusion scintigraphy to estimate the liver-to-lung shunt and exc

252 there is a need to expand the analysis of GE scintigraphy to include the separate roles of the fundus

253 demonstrate the ability of (99m)Tc-HMPAO-WBC scintigraphy to reduce the rate of misdiagnosed cases of

254 been recognized that technetium-labeled bone scintigraphy tracers can localize to myocardial amyloid

255 ance imaging and cardiac repurposing of bone scintigraphy tracers.

256 ice catheter cerebral angiography, perfusion scintigraphy, transcranial Doppler sonography, CT angiog

257 ivocal for uptake on (111)In-DTPA-octreotide scintigraphy underwent (68)Ga-DOTATATE PET.

258 Perfusion scintigraphy using (99m)Tc-labeled albumin aggregates is

259 Bone scintigraphy using (99m)Tc-labeled methylene diphosphona

260 efore surgery, all patients underwent breast scintigraphy using a high-resolution semiconductor-based

261 ssess the level of agreement between PET and scintigraphy using diagnostic amounts of (124)I and ther

262 thies, myocardial radiotracer uptake on bone scintigraphy was >99% sensitive and 86% specific for car

263 interval between (18)F-FDG PET and leukocyte scintigraphy was 7 +/- 7 d.

264 and October 2015 and for whom baseline bone scintigraphy was available.

265 crepancy between (18)F-FDG PET and leukocyte scintigraphy was classified as having possible endocardi

266 he value of (18)F-FDG PET/CT and (123)I-BZA2 scintigraphy was compared for melanoma staging.

267 Cardiac (123)I-metaiodobenzylguanidine scintigraphy was conducted in a subgroup of 29 patients

268 Scintigraphy was performed on 110 patients with primary

269 Scintigraphy was positive in 31 of 33 patients (sensitiv

270 Gastric scintigraphy was preoperatively performed in all patient

271 Clinical gamma scintigraphy was proved feasible to explore spatial- and

272 c contrast enhanced MR urography to RS renal scintigraphy was shown, with a standard deviation of app

273 Scintigraphy was true-positive in 46 of 51 and false-neg

274 (99m)Tc-MAA planar scintigraphy was used for liver-to-lung shunt estimation

275 hy was used compared with that when RS renal scintigraphy was used.

276 ing with a Tc(99m)-labelled meal followed by scintigraphy was utilized.

277 mucosal medication contact time, measured by scintigraphy, was higher for the OVB group than the NEB

278 However, a tumor-negative (131)I whole-body scintigraphy (WBS) prevails in 38%-50% of patients.

279 ve findings on radioiodine (131I) whole-body scintigraphy (WBS).

280 ariability measurements and gastric emptying scintigraphies were performed in all subjects to obtain

281 The results of (18)F-FDG PET and leukocyte scintigraphy were analyzed separately and retrospectivel

282 our pediatric radiology department for bone scintigraphy were evaluated.

283 SPECT/CT and planar scintigraphy were performed at the same posttreatment in

284 (18)F-FDG PET and leukocyte scintigraphy were performed on 39 consecutive patients a

285 e cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study.

286 nclusive results at US and (99m)Tc sestamibi scintigraphy were prospectively enrolled.

287 therapeutic radiopharmaceutical use and bone scintigraphy were unchanged.

288 t CTEPH should include ventilation-perfusion scintigraphy, which has high sensitivity and a negative

289 these tests, she was referred for whole-body scintigraphy, which revealed an unexpected finding that

290 sults were also compared with available bone scintigraphy, white blood cell scintigraphy, and (18)F-F

291 Whole-body scintigraphy with (111)In-pentetreotide has revolutioniz

292 Planar scintigraphy with (123)I/(99m)Tc-sestamibi performs well

293 udy was to compare the performance of planar scintigraphy with (123)I/(99m)Tc-sestamibi, (99m)Tc-sest

294 erwent angiographic assessment and perfusion scintigraphy with (99m)Tc-MAA before lobar (90)Y radioem

295 noma who underwent hepatic arteriography and scintigraphy with (99m)Tc-MAA using planar imaging, SPEC

296 Scintigraphy with (99m)Tc-nanocolloid was able to confir

297 ) I-FP-CIT SPECT and (123) I-MIBG myocardial scintigraphy within a few weeks of clinical diagnosis.

298 a single (111)In-girentuximab injection and scintigraphy without any treatment.

299 ymptoms alone or delayed gastric emptying by scintigraphy without gastrointestinal symptoms.

300 NaF PET were unavailable, conventional bone scintigraphy would have been ordered in 85% of patients.